Literature DB >> 3093533

Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus.

L A Frohman, T R Downs, T C Williams, E P Heimer, Y C Pan, A M Felix.   

Abstract

The effect of plasma on degradation of human growth hormone-releasing hormone (GRH) was examined in vitro and in vivo using high performance liquid chromatography (HPLC), radioimmunoassay (RIA), and bioassay. When GRH(1-44)-NH2 was incubated with human plasma, the t1/2 of total GRH immunoreactivity was 63 min (RIA). However, HPLC revealed a more rapid disappearance (t1/2, 17 min) of GRH(1-44)-NH2 that was associated with the appearance of a less hydrophobic but relatively stable peptide that was fully immunoreactive. Sequence analysis indicated its structure to be GRH(3-44)-NH2. Identity was also confirmed by co-elution of purified and synthetic peptides on HPLC. Biologic activity of GRH(3-44)-NH2 was less than 10(-3) that of GRH(1-44)-NH2. After intravenous injection of GRH(1-44)-NH2 in normal subjects, a plasma immunoreactive peak with HPLC retention comparable to GRH(3-44)-NH2 was detected within 1 min and the t1/2 of GRH(1-44)-NH2 (HPLC) was 6.8 min. The results provide evidence for GRH inactivation by a plasma dipeptidylaminopeptidase that could limit its effect on the pituitary.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3093533      PMCID: PMC423714          DOI: 10.1172/JCI112679

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  31 in total

1.  Measurement of growth hormone-releasing factor.

Authors:  L A Frohman; T R Downs
Journal:  Methods Enzymol       Date:  1986       Impact factor: 1.600

Review 2.  Physiological and clinical studies of GRF and GH.

Authors:  M O Thorner; M L Vance; W S Evans; R M Blizzard; A D Rogol; K Ho; D A Leong; J L Borges; M J Cronin; R M MacLeod
Journal:  Recent Prog Horm Res       Date:  1986

3.  L-dopa stimulates release of hypothalamic growth hormone-releasing hormone in humans.

Authors:  K Chihara; Y Kashio; T Kita; Y Okimura; H Kaji; H Abe; T Fujita
Journal:  J Clin Endocrinol Metab       Date:  1986-03       Impact factor: 5.958

4.  Metabolic clearance of insulin in man.

Authors:  S M Genuth
Journal:  Diabetes       Date:  1972-10       Impact factor: 9.461

5.  Disappearance rates of exogenous and endogenous ACTH from rat plasma measured by bioassay and radioimmunoassay.

Authors:  H Matsuyama; A Ruhmann-Wennhold; L R Johnson; D H Nelson
Journal:  Metabolism       Date:  1972-01       Impact factor: 8.694

Review 6.  Growth hormone-releasing hormone.

Authors:  L A Frohman; J O Jansson
Journal:  Endocr Rev       Date:  1986-08       Impact factor: 19.871

7.  Elimination of TRH in man.

Authors:  J Leppaluoto; P Virkkunen; H Lybeck
Journal:  J Clin Endocrinol Metab       Date:  1972-09       Impact factor: 5.958

8.  Radioimmunoassay for human growth hormone-releasing factor (hGRF 1-40): comparison of plasma immunoreactive GRF after intravenous and subcutaneous administration to rats.

Authors:  B Rafferty; D Schulster
Journal:  Mol Cell Endocrinol       Date:  1985-06       Impact factor: 4.102

9.  Effects of intravenous, subcutaneous, and intranasal administration of growth hormone (GH)-releasing hormone-40 on serum GH concentrations in normal men.

Authors:  W S Evans; M L Vance; D L Kaiser; R P Sellers; J L Borges; T R Downs; L A Frohman; J Rivier; W Vale; M O Thorner
Journal:  J Clin Endocrinol Metab       Date:  1985-11       Impact factor: 5.958

10.  Structure-activity studies on the N-terminal region of growth hormone releasing factor.

Authors:  D H Coy; W A Murphy; J Sueiras-Diaz; E J Coy; V A Lance
Journal:  J Med Chem       Date:  1985-02       Impact factor: 7.446

View more
  18 in total

Review 1.  The role of pharmacokinetics in the development of biotechnologically derived agents.

Authors:  R J Wills; B L Ferraiolo
Journal:  Clin Pharmacokinet       Date:  1992-12       Impact factor: 6.447

2.  Ectopic growth hormone-releasing hormone secretion by a metastatic bronchial carcinoid tumor: a case with a non hypophysial intracranial tumor that shrank during long acting octreotide treatment.

Authors:  Patricia Fainstein Day; Lawrence Frohman; Hernan Garcia Rivello; Jean Claude Reubi; Gustavo Sevlever; Mariela Glerean; Tomas Fernandez Gianotti; Marcelo Pietrani; Alejandra Rabadan; Silvina Racioppi; Martin Bidlingmaier
Journal:  Pituitary       Date:  2007       Impact factor: 4.107

3.  Inhibition of dipeptidyl aminopeptidase IV (DP-IV) by Xaa-boroPro dipeptides and use of these inhibitors to examine the role of DP-IV in T-cell function.

Authors:  G R Flentke; E Munoz; B T Huber; A G Plaut; C A Kettner; W W Bachovchin
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

Review 4.  Ectopic secretion of growth hormone-releasing hormone in man.

Authors:  M Losa; J Schopohl; K von Werder
Journal:  J Endocrinol Invest       Date:  1993-01       Impact factor: 4.256

5.  Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma.

Authors:  L A Frohman; T R Downs; E P Heimer; A M Felix
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

6.  Inhibition of dipeptidyl peptidase IV by fluoroolefin-containing N-peptidyl-O-hydroxylamine peptidomimetics.

Authors:  J Lin; P J Toscano; J T Welch
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

7.  Peptide stability in drug development. II. Effect of single amino acid substitution and glycosylation on peptide reactivity in human serum.

Authors:  M F Powell; T Stewart; L Otvos; L Urge; F C Gaeta; A Sette; T Arrhenius; D Thomson; K Soda; S M Colon
Journal:  Pharm Res       Date:  1993-09       Impact factor: 4.200

8.  Altered growth hormone response after growth hormone releasing hormone administration in chronic renal failure.

Authors:  R V Garcia; A Andrade; J Perez; M Courel; F F Casanueva
Journal:  J Endocrinol Invest       Date:  1991-05       Impact factor: 4.256

9.  Rapid effect of intravenous growth hormone (GH)-releasing hormone 1-44 on plasma GH levels in children.

Authors:  R Rosskamp; F Haverkamp
Journal:  Eur J Pediatr       Date:  1988-10       Impact factor: 3.183

10.  New Gaba-containing analogues of human growth hormone-releasing hormone (1-30)-amide: I. Synthesis and in vitro biological activity.

Authors:  I Mezö; M Kovács; B Szöke; E Z Szabó; J Horváth; G B Makara; G Rappay; J Tamás; I Teplán
Journal:  J Endocrinol Invest       Date:  1993-11       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.